Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
Source: SeekingAlpha
2026-03-09 13:35:15 ET
Immatics Overview
It's been quite awhile since I covered Immatics ( IMTX )—October 2023, to be exact. Back in those days , Immatics was testing its TCR-T cell therapy, IMA203 in a Phase 1 study in solid tumors. The company has since advanced anzu-cel (IMA203) in 2L melanoma and uveal melanoma....
Read the full article on Seeking Alpha
For further details see:
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.69% G/L:
$10.08 Last:
1,618,798 Volume:
$10.40 Open:
IMTX Latest News
February 05, 2026 08:32:00 am
Big Pharma's $170B Panic: Why Capital Is Rotating to Clinical Stage Oncology
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
